Selected research
Industry Research
Therapeutic Cancer Vaccines Industry Research Report 2026
Market perspective
The global Therapeutic Cancer Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Therapeutic Cancer Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Therapeutic Cancer Vaccines market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Therapeutic Cancer Vaccines market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Therapeutic Cancer Vaccines include Merck, GlaxoSmithKline, Bayer, VAXIMM, Northwest Biotherapeutics, Moderna, Mayo Clinic, Avax Technologies and Asterias Biotherapeutics and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Therapeutic Cancer Vaccines market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Therapeutic Cancer Vaccines.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Therapeutic Cancer Vaccines Market by Company
Merck
GlaxoSmithKline
Bayer
VAXIMM
Northwest Biotherapeutics
Moderna
Mayo Clinic
Avax Technologies
Asterias Biotherapeutics
Antigenics
Therapeutic Cancer Vaccines Segment by Type
Non-specific and Cytokine Strategies
Antigen Vaccine
Whole Cell Vaccine
Others
Therapeutic Cancer Vaccines Segment by Application
Breast Cancer
Prostate Cancer
Brain Tumors
Cervical Cancer
Lung Cancer
Bladder Cancer
Others
Therapeutic Cancer Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Cancer Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Cancer Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Cancer Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Therapeutic Cancer Vaccines companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Non-specific and Cytokine Strategies
- Antigen Vaccine
- Whole Cell Vaccine
- Others
Applications
- Breast Cancer
- Prostate Cancer
- Brain Tumors
- Cervical Cancer
- Lung Cancer
- Bladder Cancer
- Others
Companies covered
- Merck
- GlaxoSmithKline
- Bayer
- VAXIMM
- Northwest Biotherapeutics
- Moderna
- Mayo Clinic
- Avax Technologies
- Asterias Biotherapeutics
- Antigenics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Therapeutic Cancer Vaccines by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Non-specific and Cytokine Strategies
- 2.2.3 Antigen Vaccine
- 2.2.4 Whole Cell Vaccine
- 2.2.5 Others
- 2.3 Therapeutic Cancer Vaccines by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Breast Cancer
- 2.3.3 Prostate Cancer
- 2.3.4 Brain Tumors
- 2.3.5 Cervical Cancer
- 2.3.6 Lung Cancer
- 2.3.7 Bladder Cancer
- 2.3.8 Others
- 2.4 Assumptions and Limitations
3 Therapeutic Cancer Vaccines Breakdown Data by Type
- 3.1 Global Therapeutic Cancer Vaccines Historic Market Size by Type (2021-2026)
- 3.2 Global Therapeutic Cancer Vaccines Forecasted Market Size by Type (2027-2032)
4 Therapeutic Cancer Vaccines Breakdown Data by Application
- 4.1 Global Therapeutic Cancer Vaccines Historic Market Size by Application (2021-2026)
- 4.2 Global Therapeutic Cancer Vaccines Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Therapeutic Cancer Vaccines Market Perspective (2021-2032)
- 5.2 Global Therapeutic Cancer Vaccines Growth Trends by Region
- 5.2.1 Global Therapeutic Cancer Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Therapeutic Cancer Vaccines Historic Market Size by Region (2021-2026)
- 5.2.3 Therapeutic Cancer Vaccines Forecasted Market Size by Region (2027-2032)
- 5.3 Therapeutic Cancer Vaccines Market Dynamics
- 5.3.1 Therapeutic Cancer Vaccines Industry Trends
- 5.3.2 Therapeutic Cancer Vaccines Market Drivers
- 5.3.3 Therapeutic Cancer Vaccines Market Challenges
- 5.3.4 Therapeutic Cancer Vaccines Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Therapeutic Cancer Vaccines Players by Revenue
- 6.1.1 Global Top Therapeutic Cancer Vaccines Players by Revenue (2021-2026)
- 6.1.2 Global Therapeutic Cancer Vaccines Revenue Market Share by Players (2021-2026)
- 6.2 Global Therapeutic Cancer Vaccines Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Therapeutic Cancer Vaccines Head Office and Area Served
- 6.4 Global Therapeutic Cancer Vaccines Players, Product Type & Application
- 6.5 Global Therapeutic Cancer Vaccines Manufacturers Established Date
- 6.6 Global Therapeutic Cancer Vaccines Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Therapeutic Cancer Vaccines Market Size (2021-2032)
- 7.2 North America Therapeutic Cancer Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Therapeutic Cancer Vaccines Market Size by Country (2021-2026)
- 7.4 North America Therapeutic Cancer Vaccines Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Therapeutic Cancer Vaccines Market Size (2021-2032)
- 8.2 Europe Therapeutic Cancer Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Therapeutic Cancer Vaccines Market Size by Country (2021-2026)
- 8.4 Europe Therapeutic Cancer Vaccines Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Therapeutic Cancer Vaccines Market Size (2021-2032)
- 9.2 Asia-Pacific Therapeutic Cancer Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Therapeutic Cancer Vaccines Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Therapeutic Cancer Vaccines Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Therapeutic Cancer Vaccines Market Size (2021-2032)
- 10.2 South America Therapeutic Cancer Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Therapeutic Cancer Vaccines Market Size by Country (2021-2026)
- 10.4 South America Therapeutic Cancer Vaccines Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Therapeutic Cancer Vaccines Market Size (2021-2032)
- 11.2 Middle East & Africa Therapeutic Cancer Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Therapeutic Cancer Vaccines Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Therapeutic Cancer Vaccines Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck
- 12.1.1 Merck Company Information
- 12.1.2 Merck Business Overview
- 12.1.3 Merck Revenue in Therapeutic Cancer Vaccines Business (2021-2026)
- 12.1.4 Merck Therapeutic Cancer Vaccines Product Portfolio
- 12.1.5 Merck Recent Developments
- 12.2 GlaxoSmithKline
- 12.2.1 GlaxoSmithKline Company Information
- 12.2.2 GlaxoSmithKline Business Overview
- 12.2.3 GlaxoSmithKline Revenue in Therapeutic Cancer Vaccines Business (2021-2026)
- 12.2.4 GlaxoSmithKline Therapeutic Cancer Vaccines Product Portfolio
- 12.2.5 GlaxoSmithKline Recent Developments
- 12.3 Bayer
- 12.3.1 Bayer Company Information
- 12.3.2 Bayer Business Overview
- 12.3.3 Bayer Revenue in Therapeutic Cancer Vaccines Business (2021-2026)
- 12.3.4 Bayer Therapeutic Cancer Vaccines Product Portfolio
- 12.3.5 Bayer Recent Developments
- 12.4 VAXIMM
- 12.4.1 VAXIMM Company Information
- 12.4.2 VAXIMM Business Overview
- 12.4.3 VAXIMM Revenue in Therapeutic Cancer Vaccines Business (2021-2026)
- 12.4.4 VAXIMM Therapeutic Cancer Vaccines Product Portfolio
- 12.4.5 VAXIMM Recent Developments
- 12.5 Northwest Biotherapeutics
- 12.5.1 Northwest Biotherapeutics Company Information
- 12.5.2 Northwest Biotherapeutics Business Overview
- 12.5.3 Northwest Biotherapeutics Revenue in Therapeutic Cancer Vaccines Business (2021-2026)
- 12.5.4 Northwest Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio
- 12.5.5 Northwest Biotherapeutics Recent Developments
- 12.6 Moderna
- 12.6.1 Moderna Company Information
- 12.6.2 Moderna Business Overview
- 12.6.3 Moderna Revenue in Therapeutic Cancer Vaccines Business (2021-2026)
- 12.6.4 Moderna Therapeutic Cancer Vaccines Product Portfolio
- 12.6.5 Moderna Recent Developments
- 12.7 Mayo Clinic
- 12.7.1 Mayo Clinic Company Information
- 12.7.2 Mayo Clinic Business Overview
- 12.7.3 Mayo Clinic Revenue in Therapeutic Cancer Vaccines Business (2021-2026)
- 12.7.4 Mayo Clinic Therapeutic Cancer Vaccines Product Portfolio
- 12.7.5 Mayo Clinic Recent Developments
- 12.8 Avax Technologies
- 12.8.1 Avax Technologies Company Information
- 12.8.2 Avax Technologies Business Overview
- 12.8.3 Avax Technologies Revenue in Therapeutic Cancer Vaccines Business (2021-2026)
- 12.8.4 Avax Technologies Therapeutic Cancer Vaccines Product Portfolio
- 12.8.5 Avax Technologies Recent Developments
- 12.9 Asterias Biotherapeutics
- 12.9.1 Asterias Biotherapeutics Company Information
- 12.9.2 Asterias Biotherapeutics Business Overview
- 12.9.3 Asterias Biotherapeutics Revenue in Therapeutic Cancer Vaccines Business (2021-2026)
- 12.9.4 Asterias Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio
- 12.9.5 Asterias Biotherapeutics Recent Developments
- 12.10 Antigenics
- 12.10.1 Antigenics Company Information
- 12.10.2 Antigenics Business Overview
- 12.10.3 Antigenics Revenue in Therapeutic Cancer Vaccines Business (2021-2026)
- 12.10.4 Antigenics Therapeutic Cancer Vaccines Product Portfolio
- 12.10.5 Antigenics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst